Health CarePharmaceuticals & Biotechnology
  • Price (USD)309.05
  • Today's Change-4.78 / -1.52%
  • Shares traded721.45k
  • 1 Year change-2.58%
  • Beta--
Data delayed at least 15 minutes, as of Oct 22 2019.
More ▼

Profile data is unavailable for this security.

About the company

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

  • Revenue in USD (TTM)3.40bn
  • Net income in USD949.00m
  • Incorporated2000
  • Employees7.30k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ILMN:NSQ since
Pacific Biosciences of California IncAnnounced01 Nov 201801 Nov 2018Announced-0.67%1.24bn
Data delayed at least 15 minutes, as of Oct 22 2019.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
PerkinElmer, Inc.2.80bn249.34m9.34bn12.50k37.633.4520.973.332.242.2625.1224.370.45353.684.60224,153.304.044.514.565.2648.6946.978.909.261.315.570.438414.6123.085.18-10.626.2019.060.00
Allegion PLC2.80bn416.40m9.81bn11.00k24.0214.8619.663.504.374.6029.417.071.025.597.51254,554.5015.2111.4418.5914.5043.1243.0114.8911.351.1210.140.682819.5413.435.7126.8462.9919.44--
Waters Corporation2.41bn573.77m14.51bn7.20k27.9026.4221.346.037.797.8732.708.230.68943.074.76334,175.6016.4411.8819.4713.5958.5058.9523.8523.682.0762.080.67370.004.804.914.375.75-4.10--
Mettler-Toledo International Inc.2.96bn550.40m16.86bn16.00k31.6433.4526.485.6921.6621.52116.6720.481.144.536.02185,224.2021.0918.4228.7925.7957.5256.7718.5715.630.982819.620.69340.007.734.2915.2411.0211.63--
Keysight Technologies Inc4.23bn286.00m19.31bn13.30k69.226.5832.634.571.491.6222.2915.640.69382.726.96327,907.004.696.005.807.4558.0655.536.767.691.5611.840.37890.0021.616.07-226.47--13.85--
AMETEK, Inc.5.04bn810.70m20.15bn18.20k25.094.3219.624.003.523.5721.8620.440.58555.306.50276,999.609.418.6310.7710.0934.3936.2516.0814.501.5313.430.345815.1612.696.1629.888.185.3318.47
Agilent Technologies Inc5.09bn1.09bn23.36bn15.70k22.194.9317.844.593.403.3415.8915.310.59973.606.41343,918.9012.856.0815.227.0954.6452.1321.4312.381.7228.620.274730.559.884.7626.9031.00-1.925.64
Fortive Corp6.31bn610.20m24.13bn24.00k40.673.4425.533.821.777.7318.3920.910.44384.625.04263,066.704.789.715.8211.7251.1349.7910.7613.980.98267.920.46875.8112.101.596.890.93326.73--
Emerson Electric Co.18.29bn1.96bn42.71bn87.50k22.084.8815.312.343.143.5329.3014.230.8755.455.75209,017.109.479.1813.8813.7242.4142.8610.8312.450.850616.340.413761.9614.05-6.7322.580.0996-1.873.42
Illumina, Inc.3.40bn949.00m46.13bn7.30k49.4910.7241.7913.556.346.2722.7329.270.53092.717.87466,301.4014.2413.2717.0916.5768.8668.9026.8222.766.10--0.20540.0021.1118.59-4.4546.2026.73--
Danaher Corporation20.25bn2.44bn99.16bn71.00k40.583.2426.444.903.413.4228.2544.890.39964.475.82285,254.904.874.885.385.6055.5155.0912.1912.931.9147.370.242217.738.531.707.050.40814.0344.04
Data as of Oct 22 2019. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

45.53%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Jun 201916.78m11.41%
The Vanguard Group, Inc.as of 30 Jun 201911.20m7.62%
BlackRock Fund Advisorsas of 30 Jun 20197.83m5.33%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20196.51m4.43%
SSgA Funds Management, Inc.as of 30 Jun 20196.14m4.18%
Jennison Associates LLCas of 30 Jun 20195.98m4.07%
Edgewood Management LLCas of 30 Jun 20194.16m2.83%
Sands Capital Management LLCas of 30 Jun 20193.63m2.47%
Morgan Stanley Investment Management, Inc.as of 30 Jun 20192.76m1.88%
Geode Capital Management LLCas of 30 Jun 20191.97m1.34%
More ▼
Data from 30 Jun 2019 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.